ArticleHead and neck pathology2017
Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Paragangliomas.
Article in Head and neck pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Algorithm of genetic diagnosis for patients with head and neck paraganglioma-update.Frontiers in neurology · 2024Pooled it
- Immunohistochemistry and Mutation Analysis ofInternational journal of molecular sciences · 2020Trial
- Predictive Factors of Malignancy in Cervical Paragangliomas: A Retrospective Study.Head & neck · 2025Article
- Current Understanding of Carotid Body Paraganglioma Management.Vascular specialist international · 2025Review
- Familial Paraganglioma Presenting With Acute Coronary Syndrome and Coronary Vasospasm.JCEM case reports · 2025Article
- The Molecular Classification of Pheochromocytomas and Paragangliomas: Discovering the Genomic and Immune Landscape of Metastatic Disease.Endocrine pathology · 2024Review
- Tumor volume changes after stereotactic, hypofractionated and conventional radiotherapy in paragangliomas of head and neck.Cancer medicine · 2024Article
- DUSP1 and SOX2 expression determine squamous cell carcinoma of the salivary gland progression.Scientific reports · 2024Article
- Treatment for paraganglioma with stereotactic radiotherapy.World journal of clinical cases · 2024Article
- Clinical outcomes and challenges of surgical extirpation for carotid body paraganglioma in South Korea: a single-center retrospective study.World journal of surgical oncology · 2024Article
- Article
- Multi-Disciplinary Approach to Skull Base Paragangliomas.Brain sciences · 2023Article
- MR imaging-based risk stratification scoring system to predict clinical outcomes in carotid body tumors.Frontiers in oncology · 2023Article
- Epidemiology and Histopathology of Nasopharyngeal Neoplasms in Iran.Iranian journal of otorhinolaryngology · 2023Article
- Single-nuclei and bulk-tissue gene-expression analysis of pheochromocytoma and paraganglioma links disease subtypes with tumor microenvironment.Nature communications · 2022Article
- Contemporary management of paragangliomas of the head and neck.Laryngoscope investigative otolaryngology · 2022Review
- Microsurgical treatment of carotid body tumors using periadventitial dissection: Analysis of outcomes and prognostic factors in a neurological referral center.Surgical neurology international · 2022Article
- KDM1A promotes thyroid cancer progression and maintains stemness through the Wnt/β-catenin signaling pathway.Theranostics · 2022Article
- Clinical and histopathological principles for the diagnosis of a recurrent paraganglioma of the jugular foramen initially diagnosed as a middle ear adenoma: illustrative case.Journal of neurosurgery. Case lessons · 2021Article
- Concurrent Urinary Bladder Paraganglioma and Adrenal Phaeochromocytoma With Succinate Dehydrogenase-B Mutation.Cureus · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Updated editions of The World Health Organization Classification of Tumours Pathology & Genetics for both Head and Neck Tumours and Tumours of Endocrine Organs took place in 2016 based on consensus conferences. These editions present unification of concepts in paragangliomas and highlight expanding knowledge of their etiology. There is a major emphasis in the new bluebooks on familial/syndromic paragangliomas, representing ~40% of all head and neck paragangliomas. Ancillary use of immunohistochemical evaluation, specifically of SDHB, allows the pathologist to screen for a large subset of these potentially hereditary cases. In addition, similarly to other neuroendocrine tumors, paragangliomas are now considered to represent a continuum of risk, and are assessed in terms of risk stratification. Tumors with SDHB mutations pose the highest risk for metastasis. There is currently no validated or endorsed histologic grading system. Paragangliomas remain tumors of undetermined biologic potential and should not be termed benign.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.